|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
5/19/2011 6:44:47 AM
Needham, MA-based Celldex Therapeutics (NASDAQ: CLDX) said today it has raised $31.5 million through a stock offering. The company sold 10 million shares at $3.15 apiece, roughly a 19 percent discount to yesterday’s closing stock price of $3.88, before the deal was announced. Jefferies & Co, Wedbush Securities, Brean Murray, Carret & Co. and Roth Capital Partners, managed the offering. The stock fell about 14 percent on the news, as the sale of additional shares dilutes the value of existing ones. The cash will be used to help Celldex advance to the third and final stage of clinical trials normally required for FDA approval. Celldex said it had about $44 million as of the end of March, according to its most recent quarterly report, which it has said was enough to last into 2012.
|
|
|
|
|
|
|
|
|
|
|